NASDAQ$IMNM

Immunome Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Immunome reported full-year 2023 financial results and provided an update on recently acquired assets.

Immunome reported its full-year 2023 financial results, highlighting a transformative year marked by the merger with Morphimmune, pipeline advancement, and leadership expansion. The company is focused on developing its existing assets and expanding the pipeline with novel ADCs and RLTs.

  • Closed the merger with Morphimmune.
  • Advanced the company's pipeline.
  • Expanded the company’s leadership team.
  • Acquired two promising assets and completed a successful financing.

Headline financials

Total Revenue

$3.83M

No prior period
EPS (adj)

-$0.15

Previous: -$0.64+76.6%
R&D Expenses

$23.1K

No prior period
G&A Expenses

$19.7K

No prior period
IPR&D Expenses

$80.8K

No prior period
Interest Income

$2.72K

No prior period
Weighted Avg Shares

19.8M

No prior period
Capital Expenditures

-$349K

Previous: $72K-584.7%
Net Income

-$92.6M

Previous: -$8.4M-1002.3%
Operating Income

-$94.7M

Previous: -$7.79M-1115.5%
Gross Profit

$3.57M

No prior period
R&D Expense

$90.2M

No prior period
Stock-Based Comp

$2.88M

Previous: $1.36M+112.8%

Revenue & EPS history

Immunome · Revenue · Quarterly

$3.83M

Q4 2023
Beat estimate in 2 of 9 quarters(22%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+0.8%

Avg return

Earnings day

-2.4%

Avg return

5 days after

+0.6%

Avg return

30 days after

32%

7 / 22 earnings

Positive

+24.1%

Q4 2021

Best reaction

-10.8%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.3%-9.1%-20.0%
Q4 2025+4.7%-1.0%+1.4%
Q3 2025-5.0%+2.5%+12.3%
Q1 2025+1.1%-1.0%+15.0%
Q4 2024-4.0%-18.9%-7.7%
Q3 2024-10.8%-24.5%+0.7%
Q2 2024+4.7%+4.7%+11.9%
Q1 2024-1.3%-6.2%-3.2%
Q4 2023-2.3%-16.2%-46.2%
Q3 2023-8.1%-8.9%-12.2%
Q2 2023-1.9%-0.8%+3.9%
Q1 2023+2.3%+11.9%-6.2%
Q4 2022+20.8%+18.9%+2.3%
Q3 2022+0.0%-27.6%-8.5%
Q2 2022+19.3%+13.6%+24.7%
Q1 2022-2.6%+19.6%+46.5%
Q4 2021+24.1%+20.1%-26.3%
Q3 2021-1.0%-5.1%-9.3%
Q2 2021-3.2%-11.9%+51.2%
Q1 2021-10.7%-3.0%-2.9%
Q4 2020-1.0%-4.3%-8.3%
Q3 2020-5.5%-6.4%-6.1%
Q2 2020
Q1 2020
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro